Global public health emergencies are always shrouded in uncertainty. Mpox, which has spread beyond central Africa, is no exception. The market price of a company that makes a vaccine, Denmark’s $3.2 billion Bavarian Nordic , at least offers some clues as to what biotechnology investors are bracing for. The signals so far imply a relatively contained outbreak, but things could get worse.
Aimee Donnellan is a columnist and journalist whose work has been featured in various publications including Reuters, Republic World, Diario EL PAÍS, WAtoday, Regina Leader-Post, and HELLENIC SHIPPING NEWS Worldwide. Aimee covers a wide range of topics including finance, technology, business, and global affairs, providing insightful analysis and commentary on current events.